Evidence map›Paper›PMID 34765109›Full record

ReviewHepatic oncology2022

Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma.

Sarah Ronnebaum, Abdalla Aly, Dipen Patel, Fernando Benavente, Juan-David Rueda

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hepatic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sarah RonnebaumOPEN Health, Bethesda, MD 20814, USA.ORCID https://orcid.org/0000-0003-4787-754X
Abdalla AlyAstraZeneca, Gaithersburg, MD 20878, USA.ORCID https://orcid.org/0000-0001-7411-894X
Dipen PatelOPEN Health, Bethesda, MD 20814, USA.ORCID https://orcid.org/0000-0002-9793-7611
Fernando BenaventeAstraZeneca, Gaithersburg, MD 20878, USA.ORCID https://orcid.org/0000-0002-3079-1996
Juan-David RuedaAstraZeneca, Gaithersburg, MD 20878, USA.ORCID https://orcid.org/0000-0002-0907-7106
AstraZeneca (United States) · USOpen Health Systems Laboratory · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo identify and evaluate the similarity of all trials assessing recommended treatments for advanced hepatocellular carcinoma. MATERIALS &

methodsSingle arm and randomized trials from any phase and published any time up to February 2021 were systematically searched.

resultsFrom 5677 records reviewed, 50 trials were included in the review, and 24 for assessed for similarity. In the first-line (1L) setting, several trials assessing sorafenib were noted for enrolling patients with more severe disease and/or performance status than other 1L trials; trials within the second-line (2L) setting were generally similar. Median survival was <2 years in all trial arms.

conclusionsTrials assessing recommended treatments are largely similar and appropriate for quantitative comparisons of several efficacy and safety outcomes.

Indexed as

BCLC stageECOG performance statushepatocellular carcinomaimmuno-oncology agentsimilarity assessmentsystemic treatment

Identifiers

PMID34765109
PMCPMC8577513
OpenAlexW3197927367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.